Corcept Therapeutics (CORT) EPS (Weighted Average and Diluted) (2016 - 2026)

Corcept Therapeutics has disclosed EPS (Weighted Average and Diluted) across 11 years of filings, most recently posting -$0.3 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.3, down 276.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.35 (down 69.57% YoY), and the FY2025 annual result was $0.82, down 33.33% from the prior year.
• EPS (Weighted Average and Diluted) came in at -$0.3 for Q1 2026 at Corcept Therapeutics, down from $0.2 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.41 in Q3 2024 to a low of -$0.3 in Q1 2026.
• The 5-year median for EPS (Weighted Average and Diluted) is $0.25 (2023), against an average of $0.21.
• Across the five-year window, EPS (Weighted Average and Diluted) surged 100.0% in 2023 and sank 276.47% in 2026, its largest moves.
• Corcept Therapeutics' EPS (Weighted Average and Diluted) stood at $0.14 in 2022, then soared by 100.0% to $0.28 in 2023, then fell by 10.71% to $0.25 in 2024, then slipped by 20.0% to $0.2 in 2025, then plunged by 250.0% to -$0.3 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.3 (Q1 2026), $0.2 (Q4 2025), and $0.16 (Q3 2025), per Business Quant data.